Company intelligence / Profile preview

Deverra Therapeutics

Seattle, Washington, United Statesdeverratx.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Dilanubicel, the company's lead product, has completed a global phase 2 randomized controlled trial in patients with newly diagnosed AML. Data demonstrated a statistically significant increase in remission rates in patients who received dilanubicel as an adjuvant to standard of care chemotherapy compared to standard of care chemotherapy alone[1].

Therapeutic areas: OncologyHematologyImmunologyInfectious Diseases
Modalities: Cell therapyAllogeneic cell therapyNK cell therapyCAR-NK cell therapyStem cell therapyMyeloid cell therapy
Industry: Biotech

Drug pipeline

2 assets

dilanubicel

1 more asset in the full pipeline.

Request access →

Partnerships

Coeptis Therapeutics (DVX201 has been licensed to Coeptis Therapeutics)[1]

Beyond the preview

Go deeper on Deverra Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deverra Therapeutics.

Explore the full profile